Famotidine and neotadine in reducing pain caused by gcsf

Studying the effect of famotidine and neotadine in reducing pain caused by Granulocyte Colony-Stimulating Factor (GCSF) injection in cancer patients undergoing chemotherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210415050976N19

Enrollment

Registered

2026-04-17

Start date

2026-05-31

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer. Agranulocytosis secondary to cancer chemotherapy

Interventions

Intervention 1: The intervention group: patients received famotidine 20 mg and neotadine 10 mg orally once daily for three days prior to G-CSF injection.Famotidine (chemical formula: C16H22N6O2S) is a

Eligibility

Sex/Gender

Female

Age

30 Years to 59 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with various types of cancer who are undergoing chemotherapy and require granulocyte colony-stimulating factor (G-CSF) injections to increase their white blood cell count. Patients must have received at least one cycle of G-CSF injection. Patients must have a willingness to participate in the study and provide informed consent by signing the informed consent form.

Exclusion criteria

Exclusion criteria: Patients with specific medical conditions that may affect the evaluation of drug effects (such as severe liver or kidney diseases).

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: During and immediately after the intervention. Method of measurement: Visual analogue scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Kalani

Jahrom University of Medical Sciences

k.navid@jums.ac.ir+98 71 5434 4002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026